期刊文献+

成年男性催乳素腺瘤垂体功能减退模式 被引量:1

Hypopituitarism patterns among adult males with prolactinomas
原文传递
导出
摘要 回顾性分析107例男性催乳素腺瘤患者治疗前垂体功能减退的特点。发现该组患者生长激素轴和性腺轴减退发生率最高;且对于大腺瘤(〉1em)患者,瘤体直径增大和高催乳素血症并不明显增加垂体功能减退的发生率,但其可作为判断减退程度的指标之一。 Base on pretreatment clinical data of 107 patients, we retrospectively characterized hypopituitarism adult men harboring prolactionomas. The incidence of growth hormone deficiency and hypogonadism is the most common pattern. As to adult males harboring macroprolactinomas ( 〉 1 cm), maximal adenoma diameter and higher prolactin level are no more the primary factor causing hypopituitarism, but affecting the degree of hormone insufficiency.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2015年第10期877-879,共3页 Chinese Journal of Endocrinology and Metabolism
基金 基金项目:全国统计科学研究计划(2013LY059) 广东省教育部产学研结合项目(20128091100463) 广东省科技计划(20128010200026) 广东省医学科研基金(B2013222)
关键词 垂体功能减退症 催乳素腺瘤 成年男性 垂体 Hypopituitarism Prolatinoma Adult males Pituitary
  • 相关文献

参考文献19

  • 1Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury ( Oxfordshire, UK) [J]. Clin Endocrinol (Oxf), 2010,72(3) :377- 382.
  • 2Molitch ME. Nonfunctioning pituitary tumors and pituitary incidenta- lomas [ J ]. Endocrinol Metab Clin North Am, 2008,37 (1) :151-171.
  • 3Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas [ J]. Clin Endocrinol ( Oxf), 2006,65 (2) :265-273.
  • 4Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes : an Endocrine Society ClinicalPractice Guideline[J]. J Clin Endocrinol Metab, 2010,95(6) :2536- 2559.
  • 5Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline [ J ]. J Clin Endocrinol Metab, 2011,96 (6) :1587-1609.
  • 6Koulouri O, Auldin MA, Agarwal R, et al. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease : pituitary patients are at risk of under-replacement with levothyroxine [J]. Clin Endocrinol (Oxf), 2011,74(6) :744-749.
  • 7Schmidt IL, Lahner H, Mann K, et al. Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease [ J ]. J Clin Endocrinol Metab, 2003,88(9) :4193-4198.
  • 8Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas[ J]. J Neurooncol, 2001,54(2) :139-150.
  • 9Delgrange E, Trouillas J, Maiter D, et al. Sex-related difference in the growth of prolactinomas : a clinical and proliferation marker study [ J ]. J Clin Endocrinol Metab, 1997,82(7) :2102-2107.
  • 10Calle-Rodrigue RD, Giannini C, Scheithauer BW, et al. Prolactinomas in male and female patients: a comparative clinicopathologic study [ J]. Mayo Clin Proc, 1998,73 ( 11 ) : 1046-1052.

二级参考文献15

  • 1Wolfsberger S, Czech T, Vierhapper H, et al. Microprolactinomas in males treated by transsphenoidal surgery. Acta Neurochir (Wien),2003,145:935- 941.
  • 2Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neurooncol, 2001,54: 139- 150.
  • 3Shrivastava RK, Arginteanu MS, King WA, et al. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg,2002,97: 299 - 306.
  • 4Amar AP, Couldwell WT, Chen JC ,et al. Predictive value of serum prolactin levels measured immediately aftertranssphenoidal surgery. J Neurosurg, 2002, 97:307-314.
  • 5Wilson CB. Surgical management of pituitary tumors. J Clin Endocrinol Metab, 1997, 82:2381- 2385.
  • 6Massoud F, Serri O, Hardy J, et al. Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surg Neurol,1996, 45:341- 346.
  • 7Thomson JA, Gray CE, Teasdale GM. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up. Neurosurgery, 2002, 50:36- 40.
  • 8Perrin G, Treluyer G, Trouillas J, et al. Surgical outcome and pathological effects of bromocriptine preperative treatment in prolactiomas. Path Res Pract , 1991,187:587- 592.
  • 9Gokalp HZ, Deda H, Attar A,et al. The neurosurgical management of prolactinomas. J Neurosurg Sci ,2000,44:128- 132.
  • 10Tyrrell JB, Lamborn KR, Hannegan LT, et al. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and longterm results. Neurosurgery, 1999,44:254- 263.

共引文献2

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部